4.420USD+4.25%Mkt Cap: 353.72M USDP/E: —Last update: 2026-05-22
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the re…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap353.72M USD
Enterprise Value83.94M USD
Revenue (TTM)—
Gross Profit-159.32M USD
Net Income (TTM)-158.35M USD
Revenue/Share—
Last Price4.420 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.06
PEG—
EV/EBITDA-0.44
EV/Revenue—
P/S—
P/B1.45
EPS (TTM)-2.11
EPS (Forward)-1.39
52W Range
2.78045% of range6.450
52W High6.450 USD
52W Low2.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-57.49%
ROA-50.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.03M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-24.80%
Net Debt-255.37M USD
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.00
Current Ratio7.89
Quick Ratio7.67
Book Value/Sh2.920 USD
Cash/Share3.199 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)8.667 USD
Target Range6.000 USD – 10.00 USD
# Analysts3
Ownership
Shares Out.80.03M
Float60.24M
Insiders13.39%
Institutions80.14%
Short Interest
Short Ratio24.4d
Short % Float12.07%
Short % Out.9.36%
Shares Short7.49M
Short (prev mo.)7.59M
Technical
SMA 505.450 (-18.9%)
SMA 2004.024 (+9.8%)
Beta0.38
S&P 52W Chg28.31%
Avg Vol (30d)316.25K
Avg Vol (10d)427.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—